Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), administered as single agent in patients (pts) with colorectal cancer (CRC) refractory to standard regimens

被引：0
|
作者：
Rimassa, L. [1 ,2 ,3 ,4 ]
Sobrero, A. F. [1 ,2 ,3 ,4 ]
Santoro, A. [1 ,2 ,3 ,4 ]
Andretta, V. [1 ,2 ,3 ,4 ]
Gregorc, V. [1 ,2 ,3 ,4 ]
Sclafani, F. [1 ,2 ,3 ,4 ]
Caprioni, F. [1 ,2 ,3 ,4 ]
Caligaris-Cappio, F. [1 ,2 ,3 ,4 ]
Lambiase, A. [1 ,2 ,3 ,4 ]
Bordignon, C. [1 ,2 ,3 ,4 ]
机构：
[1] Inst Clin Humanitas, Rozzano, Italy
[2] Osped San Martino Genova, Genoa, Italy
[3] Ist Sci San Raffaele, Milan, Italy
[4] MolMed, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4088
引用
收藏
页数：2
相关论文
共 50 条
  • [21] NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM): Preliminary results of multicenter phase II study
    Gregorc, V.
    Zucali, P.
    Ceresoli, G. L.
    Noberasco, C.
    Bajetta, E.
    Santoro, A.
    Vigano, M. G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma
    Santoro, A.
    Pressiani, T.
    Citterio, G.
    Rossoni, G.
    Donadoni, G.
    Pozzi, F.
    Rimassa, L.
    Personeni, N.
    Bozzarelli, S.
    Rossoni, G.
    Colombi, S.
    De Braud, F. G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    BRITISH JOURNAL OF CANCER, 2010, 103 (06) : 837 - 844
  • [23] Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma
    A Santoro
    T Pressiani
    G Citterio
    G Rossoni
    G Donadoni
    F Pozzi
    L Rimassa
    N Personeni
    S Bozzarelli
    G Rossoni
    S Colombi
    F G De Braud
    F Caligaris-Cappio
    A Lambiase
    C Bordignon
    British Journal of Cancer, 2010, 103 : 837 - 844
  • [24] Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours
    Gregorc, Vanesa
    Citterio, Giovanni
    Vitali, Giordano
    Spreafico, Anna
    Scifo, Paola
    Borri, Anna
    Donadoni, Giovanni
    Rossoni, Gilda
    Corti, Angelo
    Caligaris-Cappio, Federico
    Del Maschio, Alessandro
    Esposito, Antonio
    De Cobelli, Francesco
    Dell'Acqua, Flavio
    Troysi, Antonella
    Bruzzi, Paolo
    Lambiase, Antonio
    Bordignon, Claudio
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (01) : 198 - 206
  • [25] Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours
    V Gregorc
    A Santoro
    E Bennicelli
    C J A Punt
    G Citterio
    J N H Timmer-Bonte
    F Caligaris Cappio
    A Lambiase
    C Bordignon
    C M L van Herpen
    British Journal of Cancer, 2009, 101 : 219 - 224
  • [26] PHASE I AND PHARMACODYNAMIC STUDY OF NGR-HTNF ADMINISTERED AT HIGH DOSES IN REFRACTORY PATIENTS WITH SOLID TUMORS
    Zucali, P. A.
    Santoro, A.
    Simonelli, M.
    De Vincenzo, F.
    Lorenzi, E.
    Rimassa, L.
    Balzarini, L.
    Quagliuolo, V.
    Lambiase, A.
    Bordignon, C.
    ANNALS OF ONCOLOGY, 2010, 21 : 173 - 173
  • [27] Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors.
    Simonelli, M.
    Santoro, A.
    Zucali, P. A.
    Rimassa, L.
    De Vincenzo, F.
    Pressiani, T.
    Tronconi, M. C.
    Carnaghi, C.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
    Lorusso, D.
    Scambia, G.
    Amadio, G.
    di Legge, A.
    Pietragalla, A.
    De Vincenzo, R.
    Masciullo, V.
    Di Stefano, M.
    Mangili, G.
    Citterio, G.
    Mantori, M.
    Lambiase, A.
    Bordignon, C.
    BRITISH JOURNAL OF CANCER, 2012, 107 (01) : 37 - 42
  • [29] Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
    D Lorusso
    G Scambia
    G Amadio
    A di Legge
    A Pietragalla
    R De Vincenzo
    V Masciullo
    M Di Stefano
    G Mangili
    G Citterio
    M Mantori
    A Lambiase
    C Bordignon
    British Journal of Cancer, 2012, 107 : 37 - 42
  • [30] Vascular effects of the vascular targeting agent NGR-hTNF in patients (pts) with advanced solid cancer: A dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) EORTC study.
    Van Laarhoven, H.
    Desar, I.
    Asten, J.
    Fiedler, W. M.
    Marreaud, S.
    Timmer-Bonte, J. N.
    Teroert, E.
    Bordignon, C.
    Heerschap, A.
    Van Herpen, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345